Methotrexate in Rheumatoid Arthritis: An Update

Drugs

Volumn 47, Issue 1, 1994, Pages 25-50

  Bannwarth, Bernard ^a   Labat, Laurence ^a   Moride, Yola ^a   Schaeverbeke, Thierry ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; CARCINOGENESIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; INFECTIOUS COMPLICATION; LIVER TOXICITY; LUNG TOXICITY; PHARMACODYNAMICS; REPRODUCTIVE TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS; SYNOVIOCYTE;

HUMAN HERPESVIRUS 4;

EID: 0027953530     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199447010-00003     Document Type: Review

References (174)

1. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?
2. Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings
3. Nonperipheral accelerated nodulosis in a methotrexate-treated rheumatoid arthritis patient
4. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis
5. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment
6. Pancytopenia associated with low dose methotrexate therapy. A regional survey
7. Aplasie médullaire dans une polyarthrite rhumatoïde traitée par le méthotrexate à faible dose
8. Cryptococcosis associated with low-dose methotrexate for arthritis
9. Taux de maintenance thérapeutique du méthotrexate au cours de la polyarthrite rhumatoïde. Etude prospective de 191 cas
10. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate
11. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study
12. Severe pancytopenia in a patient taking low dose methotrexate and probenecid
13. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy
14. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis
15. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients
16. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?
17. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis
18. Fatal cardiac nodules in a patient with rheumatoid arthritis treated with low dose methotrexate
19. Severe bone marrow failure due to low dose oral methotrexate
20. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice
21. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis
22. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate
23. Polyglutamation of methotrexate. Is methotrexate a prodrug?
24. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis
25. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid athritis
26. Non-Hodgkin’s lymphoma, rheumatoid arthritis and methotrexate
27. Thymoma associated with rheumatoid arthritis in a patient taking methotrexate
28. Possible efficacy of hydroxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis
29. Molecular mechanism of methotrexate action in inflammation
30. Methotrexate-associated, early-onset pancytopenia in rheumatoid arthritis
31. Antirheumatic drugs: a proposed new classification
32. Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis
33. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate
34. Benefit of G-CSF for methotrexate-induced neutropenia in rheumatoid arthritis
35. Methotrexate induced pneumonitis: appearance four weeks after discontinuation of treatment
36. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study
37. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses
38. Use of short-term efflcacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
39. Methotrexate and nonsteroidal antiinflammatory drug interactions
40. Aspirin, hydroxychloroquine and hepatic enzymes abnormalities with methotrexate in rheumatoid arthritis
41. The relative toxicity of disease-modifying antirheumatic drugs
42. Proposition: methotrexate should not be the first secondline agent to be used in rheumatoid arthritis if NSAIDs fail
43. Rational use of disease-modifying antirheumatic drugs
44. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
45. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
46. Methotrexate in rheumatoid arthritis
47. Methotrexate and rheumatoid arthritis
48. Toxicity to methotrexate in rheumatoid arthritis
49. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit
50. Pancytopenia from using trimethoprim and methotrexate
51. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of a case and review of the literature
52. Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis
53. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial
54. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis
55. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression
56. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs
57. Mechanisms of action of disease modifying antirheumatic drugs
58. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies
59. Effect of folinic acid on tissue residence and excretion of methotrexate in rats
60. Methotrexate in rheumatoid arthritis
61. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption
62. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients
63. Traitement de la polyarthrite rhumatoïde par le méthotrexate
64. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate
65. Methotrexate-associated bone marrow suppression following surgery
66. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole
67. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study
68. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
69. Brief report: reversible lymphomas associated with Epstein-Barr virus occuring during methotrexate therapy for rheumatoid arthritis and dermatomyositis
70. Reconsideration of the risk of post-arthroplasty infection in patients treated with methotrexate
71. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases
72. Hepatotoxicity of methotrexate in rheumatic diseases
73. Pancytopenia induced by low-dose methotrexate for rheumatoid arthritis
74. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review
75. Winning the battle, losing the war? Another editorial about rheumatoid arthritis
76. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers
77. Outcome of first-trimester exposure to low dose methotrexate in eight patients with rheumatic disease
78. Low dose methotrexate and NSAID induced ‘mild’ renal insufficiency and severe neutropenia
79. Methotrexate 1989 — the evolving story
80. Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: where are we going?
81. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates
82. Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findings
83. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
84. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples
85. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
86. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study
87. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate
88. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients
89. Trois cas de pneumopathie au cours du traitement de la polyarthrite rhumatoïde par le méthotrexate
90. Effets du méthotrexate sur la synthèse de leucotriènes et de dérivés de la lipoxygénase par les polynucléaires au cours de la polyarthrite rhumatoïde
91. Pneumopathie aiguë au cours du traitement d’une polyarthrite rhumatoïde sévère par méthotrexate à faibles doses en administration orale fractionnée
92. Pseudo-lymphome B sous méthotrexate au cours de la polyarthrite rhumatoïde. Abstract
93. Low dose methotrexate pneumonitis in rheumatoid arthritis
94. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis
95. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment
96. Methotrexate
97. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians
98. Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human fibroblasts
99. The efficacy and toxicity of a constant low dose of methotrexate as a treatment of intractable rheumatoid arthritis: an open prospective study
100. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice
101. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis. A randomized, double blind 26-week trial
102. Folic acid supplementation during methotrexate therapy: it makes sense
103. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate
104. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
105. Methotrexate pneumonitis in rheumatoid arthritis. A dramatic response to treatment
106. In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine
107. Fatal methotrexate pneumonitis in rheumatoid arthritis
108. Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study
109. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis
110. Immunologie studies of rheumatoid arthritis patients treated with methotrexate
111. Porphyria cutanea tarda associated with methotrexate therapy
112. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis
113. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate
114. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate
115. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
116. Delayed methotrexate pneumonitis in rheumatoid arthritis
117. Methotrexate osteopathy in rheumatic disease
118. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis
119. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study
120. Can methotrexate reduce the renal toxicity of parenteral gold?
121. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature
122. Methotrexate
123. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis
124. Radiologie progression during intramuscular methotrexate treatment of rheumatoid arthritis
125. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature
126. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
127. Methotrexate: mechanism of action in rheumatoid arthritis
128. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system
129. Methotrexate. The relationship between dose and clinical effect
130. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis
131. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis
132. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis
133. Complications of immunosuppression associated with weekly low dose methotrexate
134. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis, results of a multicenter, randomized, double-blind, placebo-controlled trial
135. High dose intravenous methotrexate for refractory rheumatoid arthritis
136. Methotrexate pharmacokinetics in patients with rheumatoid arthritis
137. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit?
138. Methotrexate — the rapidly acting drug
139. 4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate
140. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?
141. Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions
142. Aspirin alters methotrexate disposition in rheumatoid arthritis patients
143. Folate supplementation in methotrexate-treated rheumatoid arthritis patients
144. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine®) in the treatment of rheumatoid arthritis
145. Malignant lymphoma in a patient with rheumatoid arthritis treated with lowdose methotrexate
146. Oral methotrexate in the treatment of Felty’s syndrome
147. Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? idiosyncrasy?
148. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole
149. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
150. Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough?
151. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis
152. Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines
153. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety
154. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis
155. Low-dose methotrexate therapy and hepatotoxicity. The view of the hepatologist
156. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy
157. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirthy-six-week, double-blind trial
158. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis
159. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial
160. The effect of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofln
161. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update
162. Studies on the effect of low dose methotrexate on rat adjuvant arthritis
163. Central nervous system toxicity associated with weekly low-dose methotrexate treatment
164. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologie disorder
165. Methotrexate and histologic abnormalities: a meta-analysis
166. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis
167. Methotrexate and rheumatoid arthritis
168. Methotrexate therapy in rheumatoid arthritis
169. New perspectives of secondary and tertiary therapy for rheumatoid arthritis
170. Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis
171. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial
172. The effect of age on methotrexate efficacy and toxicity
173. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts
174. Methotrexate transport in the human intestine